Sign In
Buy BDTX
$1.61
-0.0500 (-3.01%)
At Close: Jun 22, 2026
Stocks To Watch: Big Focus On Big Tech
08:26am, Saturday, 25'th Jul 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Black Diamond Therapeutics (BDTX) Investor Presentation - Slideshow
02:54pm, Wednesday, 24'th Jun 2020
The following slide deck was published by Black Diamond Therapeutics, Inc. in conjunction with this event.
Black Diamond Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
11:45am, Tuesday, 16'th Jun 2020
CAMBRIDGE, Mass. and NEW YORK, June 16, 2020 -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development.
Black Diamond Therapeutics to Present at the Jefferies Virtual Healthcare Conference
11:45am, Wednesday, 27'th May 2020
CAMBRIDGE, Mass. and NEW YORK, May 27, 2020 -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development.
Black Diamond Therapeutics Announces Accepted Abstract for Lead Product Candidate BDTX-189 at American Society of Clinical Oncology 2020
09:15pm, Wednesday, 13'th May 2020
CAMBRIDGE, Mass. and NEW YORK, May 13, 2020 -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development.
Black Diamond Therapeutics Reports First Quarter 2020 Financial Results and Corporate Update
11:45am, Tuesday, 12'th May 2020
Black Diamond Therapeutics, Inc. (BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today reported financial results fo
Black Diamond Therapeutics to Present at the Bank of America Global Research Health Care Conference 2020
11:45am, Wednesday, 06'th May 2020
CAMBRIDGE, Mass. and NEW YORK, May 06, 2020 -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development.
3 Biotech Stocks With Plenty of Upside in the Pipeline
03:46pm, Tuesday, 05'th May 2020
A sense of cautious optimism is looming over the Street given the progress in the reopening of the U.S. economy, and while the recent uptick isn’t necessarily indicative of a full recovery, it’s c
The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda
12:40pm, Wednesday, 29'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 28.) * AstraZeneca plc (NYSE: AZN) * Arcturus Therapeu
Zacks Investment Research Upgrades I-Mab (NASDAQ:BDTX) to Strong-Buy
09:38am, Wednesday, 29'th Apr 2020
I-Mab (NASDAQ:BDTX) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research note issued on Monday, Zacks.com reports. The firm currently has a $47
The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update
11:36am, Tuesday, 28'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) * AstraZeneca plc (NYSE: AZN) * Alnylam Pharmaceuti
New Strong Buy Stocks for April 27th
02:40pm, Monday, 27'th Apr 2020
New Strong Buy Stocks for April 27th
New Strong Buy Stocks for April 27th
02:40pm, Monday, 27'th Apr 2020
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Financial Contrast: I-Mab (NASDAQ:BDTX) and Spark Therapeutics (NASDAQ:ONCE)
09:06am, Wednesday, 22'nd Apr 2020
I-Mab (NASDAQ:BDTX) and Spark Therapeutics (NASDAQ:ONCE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recom
I-Mab (NASDAQ:BDTX) Given Consensus Rating of "Strong Buy" by Analysts
10:56am, Saturday, 18'th Apr 2020
I-Mab (NASDAQ:BDTX) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. Four investment
